The company's new KidneyCare test will include AlloSure for rejection, AlloMap for quiescence, and Cibiltech's AI algorithm for graft health information.
The company reported $26 million in total revenues for the quarter and said that testing services revenues more than doubled year over year.
Cincinnati, Ohio-based Meridian will acquire Quebec City-based GenePOC for $120 million, and hopes to quickly convert customers to a PCR-based instrument.
The firms will integrate Caris' molecular profiling services with Pharmatech's clinical trials recruitment and network services to further precision medicine.
Elucigene has been developing in vitro diagnostics for oncology and reproductive health, including tests for cystic fibrosis screening and prenatal fetal aneuploidy screening.
Canopy aims to use Zellkraftwerk's microfluidic cell-capture technology to further develop drug-development research and biomarker discovery.
While total revenues were up less than 1 percent, the Diagnostics division grew revenues 5 percent. Discovery & Analytical Solutions dipped 2 percent.
The acquisition of OTTR Complete Transplant Management will enable CareDx to integrate the EMRs of patients at transplant centers with longitudinal patient surveillance data.
The acquisition will allow the firms to provide annotated biospecimens, as well as sequencing, bioinformatics, and lab services to hospitals and clinicians.
Prescient will further the development and commercialization of the Infiniti Neural Response Panel to identify patients who may be at risk for opioid use disorder.
A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.
The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.
Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.
In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.